Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.

ABSTRACT:

SUBMITTER: Choudhury NJ 

PROVIDER: S-EPMC7713518 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature